Cristália invests for lean production

The national laboratory Cristália is investing $ 160 million in the production of active ingredients Oncology (cancer treatment) and peptide (biomolecules) for medicines, as well as a biotechnology laboratory, in its industrial plant in Itapira (SP). The investments are a result of verticalization of production process of pharmaceutical and farmoquímico segments (inputs).
"Partnerships between public and private laboratories is the expression of the Government's purchasing power. In every country in the world is done that way. In Brazil, this policy comes at the right time. After the strengthening of the pharmaceutical industry with generics, the investment in the production of chemicals is essential to the growth and reduction in the deficit of the trade balance in the area of health, "says the President of Cristália Ogari, P.
Cristalia has partnered for the Productive Development (PDP) with Fiocruz in Rio, with the participation of AlfaRio, for the production of cancer drug imatinib mesylate.
The drug is indicated for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal (malignant tumour of the intestine). It is estimated that, with the initiative, only with this medicine, the unified Health System (SUS) get savings of r $ 337 million, over the next four years.
Cristalia is part of Orygen Biotechnology, pharmaceutical company created with support from the Government to produce medicines Biosimilars in partnership with the Biolab and Eurofarma. Currently, the company sells 180 medicines.
"It's all a matter of scale. With the largest muscles obtained from generic policy, the thread farmoquímico can experience an unprecedented boom, "says Pacheco. According to the businessman, the verticalization in the productive process allows the Brazilian industrial park be able to manufacture the active ingredient to the final product.
Cristalia has 49 registered patents and is responsible for 24 of the 54 PDPs for transferring technology to public laboratories. In 2012, the billing was r $ 1.2 billion, with an increase of 56% on 2011.